Lilly Q2 2026 Earnings Show U.S. Launch Inflection Poised Amid Novo Competition

Foundayo launch: why the U.S. curve was slower, likely U.S. inflection timing, and what Novo competition may change in ex-U.S. markets

1) What factors contributed to Foundayo’s slower-than-expected U.S. launch?

From management commentary, the “slower-than-anticipated” U.S. launch pace appears to be primarily an execution/transition issue typical of new launches, rather than a demand problem:

• Inventory build and data “noise” early in launch: Management pointed out that early launch periods involve an inventory build and that reported prescription/sales data often contain “sell-in” dynamics and overall noise that can make early curves look slower than the underlying demand trend. ¹²
• Commercial ramp required across the access + awareness stack: Lilly said it is working on three main levers—educating physicians, improving access/affordability, and building consumer awareness—and that progress has been made as those elements came online. ³
• U.S. coverage/access milestones were still unfolding: Lilly noted that it secured commercial access across all 3 major PBMs in June and then began broad DTC marketing to build consumer awareness afterward. ⁴
• Marketing/sampling and physician adoption were still ramping: Management described extensive promotion/sampling and an expanding prescriber base, including an increase from 8,000 prescribers previously discussed to 36,000 prescribers. ⁵
• An inflection had to wait for both access and adoption to compound: Management explicitly connected momentum to increasing access and HCP adoption, implying that early U.S. uptake may have lagged until those adoption loops strengthened. ³⁶

Bottom line (U.S.): The excerpted reasons are largely “early launch mechanics” (inventory/sell-in effects + initial market education and adoption ramp) rather than a core product limitation. ¹²³⁴

2) When might an inflection occur in the U.S.?

Lilly’s commentary gives a concrete timing marker:

• Late July inflection in the U.S.: Management stated that “the last week of July” they were seeing an inflection, with volume nearly doubling versus a month earlier, and new starts at roughly “1 out of 4.” ³

They also reinforce that this is expected to continue “over the coming quarters” as access and awareness grow and as physician adoption continues. ³⁶

3) Outside-U.S. markets: how will competitive dynamics (including Novo’s entry) affect Foundayo’s launch trajectory?

The excerpts don’t quantify Foundayo-specific share loss/gain due to Novo in each country; however, they do provide three directly relevant competitive-dynamics insights that inform how Novo’s scaling could affect trajectory:

A) Marketplace expansion may matter as much as share capture

• Lilly emphasized that outside the U.S., with market share leadership already established for Lilly’s incretin portfolio, “market expansion will be key” to sustainable growth—suggesting that competition primarily influences how fast the market expands and how quickly patients convert, not whether growth is possible at all. ⁶

B) Expect uptake to be influenced by reimbursement and access build (not only efficacy)

• Lilly stressed that there is no “gating of launches” due to supply and that the focus is on early launch dynamics while acknowledging that outside-U.S. reimbursement takes time; this implies competitive entries can be “absorbed” if Lilly maintains access and supply momentum, but could still shift the conversion rate toward the newcomer in markets where payer coverage is faster. ²⁷

C) Novo’s scaling will add competitive pressure to first movers in multiple large ex-U.S. markets

• Management referenced that Novo is scaling launches for their oral pill in key ex-U.S. countries including the U.K. and Germany. ¹
• While the excerpt does not state exactly how Novo changes Foundayo’s trajectory country-by-country, Lilly frames the overall defense strategy as staying positioned across access, patient education, and portfolio differentiation, with Lilly noting that outside-U.S. incretin share dynamics can remain resilient even if a “second oral” enters. ²

Interpretation consistent with the excerpt: Novo’s entry increases the probability that competitive dynamics will raise the bar for incremental share gains, but Lilly’s guidance implies that the trajectory can still improve as long as (1) market expansion continues, (2) reimbursement and access widen, and (3) physician/consumer awareness continues to build despite added competitive options. ¹²⁶

4) Lessons from UAE share dynamics with Novo’s entry

Lilly’s excerpt contains a question from analysts that cites a specific “Novo got 50% share within 3 weeks” claim, and Lilly responded with UAE learning framed around early demand plus the importance of early-data interpretation:

• UAE early start and market expansion signal: Lilly said it was encouraged by the start in UAE, with early signals showing orals expanding the market. ²
• Held incretin share even with a second oral entering: Lilly said “Lilly’s combined incretin share held steady, even if we had a second oral entering the market.” ²
• Early-data caution and sell-in/inventory effects: Lilly cautioned that early data are “very early” and the dataset has “a lot of noise,” especially because much referenced activity is sell-in data affected by inventory build. ²

Lesson distilled from the excerpted UAE framing: Even when a competitor enters quickly and captures substantial early share (as implied by the question), Lilly’s management view emphasizes (a) the possibility that market expansion can offset competitive churn and (b) the need to interpret early share curves carefully due to inventory/sell-in distortions. ¹²

Summary answers (directly to the question)

• Why U.S. was slower than expected: Early launch “mechanics” (inventory build and noisy sell-in/sales data) plus time needed to fully stand up physician education, access/affordability (PBM coverage in June), and consumer awareness (DTC marketing after June). ¹²³⁴
• When U.S. inflection might occur: Late July, with volume nearly doubling vs a month earlier and new starts around 1 out of 4, followed by expectations for continued growth across subsequent quarters. ³
• How Novo competition may affect ex-U.S. Foundayo trajectory: Novo’s scaling (e.g., U.K., Germany) increases competitive pressure, but Lilly’s framework suggests growth depends heavily on market expansion and sustained access/reimbursement progress; Lilly also cited that combined incretin share held steady even after another oral entered, implying resilience when the overall oral category expands. ¹²⁶
• UAE lessons with Novo entry: Early UAE demand suggested orals can expand the category; Lilly reported combined incretin share held steady despite an additional oral entering, while also stressing that early share/sales signals can be distorted by noise and inventory/sell-in dynamics. ²